2024
Concordance and discordance of anticoagulation assays in children supported by ECMO: The truth is out there
Carmona C, Bain J, Karam O. Concordance and discordance of anticoagulation assays in children supported by ECMO: The truth is out there. Perfusion 2024, 40: 1592-1599. PMID: 39719141, DOI: 10.1177/02676591241309841.Peer-Reviewed Original ResearchActivated partial thromboplastin timeExtracorporeal membrane oxygenationICU-free daysPediatric ECMO patientsHeparin doseECMO patientsExtracorporeal membrane oxygenation studiesExtracorporeal membrane oxygenation indicationAssociated with increased bleedingAssociation of bleedingPrevalence of discordancePartial thromboplastin timeAssociated with fewer bleedingRespiratory failureMembrane oxygenationClinical outcomesAnticoagulation protocolHeparin titrationLogistic regression modelsThromboplastin timeBleedingTitration strategyPrevent complicationsClotting eventsPatientsAssessing the Reliability of the Bleeding Assessment Scale in Critically Ill Children (BASIC) Definition: A Prospective Cohort Study
Nellis M, Chegondi M, Willems A, Alqatani M, McMichael A, Aran A, Lerner R, Karam O, Investigators A. Assessing the Reliability of the Bleeding Assessment Scale in Critically Ill Children (BASIC) Definition: A Prospective Cohort Study. Pediatric Critical Care Medicine 2024, 26: e3-e11. PMID: 39560732, PMCID: PMC11774477, DOI: 10.1097/pcc.0000000000003638.Peer-Reviewed Original ResearchCritically Ill ChildrenAssessment ScaleIll childrenBleeding severityIntra-rater reliabilityInter-rater reliabilityCohort of critically ill childrenChildren Aged 0Prospective cohort studyAssociated with increased 28-day mortalityEvaluation of bleedingActivated partial thromboplastin timeBedside nursesPatient demographic dataPartial thromboplastin timeTransfused blood componentsLonger hospital lengthParticipating PICUsCohort studyHemostatic medicationsDiverse cohortInotropic supportBleeding eventsSevere bleedingPlatelet count
2023
Comprehensive Characterization of Coagulation Parameters in Venous Malformations
Restrepo V, Pine A, Butt A, Chang E, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder H, Tormey C, Nassiri N, Lee A, Prozora S. Comprehensive Characterization of Coagulation Parameters in Venous Malformations. Blood 2023, 142: 27. DOI: 10.1182/blood-2023-190609.Peer-Reviewed Original ResearchHigher thrombin-antithrombin complexesNormal D-dimerThrombin-antithrombin complexPlasminogen activator inhibitor-1Localized intravascular coagulopathyInternational normalized ratioD-dimerVenous malformationsCoagulation parametersPartial thromboplastin timeCoagulation testsFactor VIIIVWF activityChart reviewMost patientsHematology clinicProthrombin timeTissue involvementVWF antigenVon Willebrand factor antigenHigher TAT levelsMultiple coagulation parametersBaseline patient characteristicsRetrospective chart reviewCoagulation test resultsAcquired Hemophilia A: A Rare, Acquired Coagulopathy in the Postpartum Setting
Oberlin A, Krenitsky N, Gandhi C, Akpan I, Eisenberger A, Landau R, Yurteri-Kaplan L, Nathan L, Sheen J, LaSala A, D'Alton M. Acquired Hemophilia A: A Rare, Acquired Coagulopathy in the Postpartum Setting. American Journal Of Perinatology Reports 2023, 13: e85-e88. PMID: 38033602, PMCID: PMC10684337, DOI: 10.1055/a-2198-7888.Peer-Reviewed Case Reports and Technical NotesPostpartum hemorrhageRare cause of postpartum hemorrhageBlood productsInterventional radiologyIsolated prolonged activated partial thromboplastin timeCause of postpartum hemorrhageProlonged activated partial thromboplastin timeUnits of blood productsPartial thromboplastin timeIR embolizationRefractory bleedingMaternal morbidityPregnancy-associatedAcquired coagulopathiesPostpartum bleedingPostpartum patientsMassive transfusionRare causeRecurrent episodesHemophilia AMultiple surgeriesThromboplastin timeFactor VIIIBleedingEmbolizationAssociation of age with perioperative morbidity among patients undergoing surgical management of minor burns
Knoedler S, Matar D, Knoedler L, Obed D, Haug V, Gorski S, Kim B, Kauke-Navarro M, Kneser U, Panayi A, Orgill D, Hundeshagen G. Association of age with perioperative morbidity among patients undergoing surgical management of minor burns. Frontiers In Surgery 2023, 10: 1131293. PMID: 36923377, PMCID: PMC10008887, DOI: 10.3389/fsurg.2023.1131293.Peer-Reviewed Original ResearchBlood urea nitrogenPartial thromboplastin timeMinor burnsHospital staySurgical managementMajor burnsRisk factorsBody burnsThromboplastin timeUrea nitrogenWhite blood cell countNon-home dischargeACS-NSQIP databasePredictive risk factorsWhite blood countBlood cell countAverage operation timeMulti-institutional databaseShorter mean lengthAssociation of ageLower mortality rateThird-degree burnsSecond-degree burnsOlder patientsPerioperative morbidity
2022
Alterations in Pre/Post Oxygenator Flows Due to Fibrin Deposition in the CardioHelp System—A Case Report
Wahl T, Stokes A, Varner C, Zeybek B, Bardia A. Alterations in Pre/Post Oxygenator Flows Due to Fibrin Deposition in the CardioHelp System—A Case Report. Journal Of ExtraCorporeal Technology 2022, 54: 239-241. DOI: 10.1051/ject/202254239.Peer-Reviewed Original ResearchExtracorporeal membrane oxygenationActivated partial thromboplastin timeVeno-venousFibrin depositionExtracorporeal membrane oxygenation supportPartial thromboplastin timeCOVID-19 pneumoniaMembrane oxygenationCoagulation statusTherapeutic rangeCase reportECMO circuitClot locationThromboplastin timeAnticoagulation goalsBlood flowPatient outcomesClotPatientsCircuit pressureDelta pressureCardiohelpDecreased flowFibrinPatient vitalsAlterations in Pre/Post Oxygenator Flows Due to Fibrin Deposition in the CardioHelp System-A Case Report.
Wahl T, Stokes A, Varner C, Zeybek B, Bardia A. Alterations in Pre/Post Oxygenator Flows Due to Fibrin Deposition in the CardioHelp System-A Case Report. Journal Of ExtraCorporeal Technology 2022, 54: 239-241. PMID: 36742210, PMCID: PMC9891478, DOI: 10.1182/ject-239-241.Peer-Reviewed Original ResearchConceptsExtracorporeal membrane oxygenationActivated partial thromboplastin timeVeno-venousFibrin depositionExtracorporeal membrane oxygenation supportPartial thromboplastin timeCOVID-19 pneumoniaMembrane oxygenationCoagulation statusTherapeutic rangeCase reportECMO circuitClot locationThromboplastin timeAnticoagulation goalsBlood flowPatient outcomesClotPatientsCircuit pressureDelta pressureCardiohelpDecreased flowFibrinPatient vitalsThe relationship between INTEM/HEPTEM coagulation time ratio and heparin plasma concentration in obstetric patients: an exploratory in vitro investigation
Katz D, Leffert L, Getrajdman C, Sison M, Shin DW, Lin HM, Butwick A. The relationship between INTEM/HEPTEM coagulation time ratio and heparin plasma concentration in obstetric patients: an exploratory in vitro investigation. Journal Canadien D'anesthésie 2022, 69: 597-604. PMID: 35102496, DOI: 10.1007/s12630-022-02193-5.Peer-Reviewed Original ResearchConceptsObstetric patientsUnfractionated heparinConcentration of heparinHeparin activityHeparin concentrationPartial thromboplastin time (aPTT) testingCT ratioCare coagulation testsHeparin plasma concentrationsResultsSeventy-seven patientsPartial thromboplastin timeUncomplicated pregnanciesThird trimesterNeuraxial anestheticPlasma concentrationsCoagulation testsThromboplastin timeBlood samplesPatientsHeparinAPTTHematocrit rangeVitro investigationBloodTime ratio
2021
Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient
Jacobs JW, Gisriel SD, Iyer K, Rinder HM. Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient. Journal Of Thrombosis And Thrombolysis 2021, 53: 945-949. PMID: 34697688, PMCID: PMC8544916, DOI: 10.1007/s11239-021-02591-4.Peer-Reviewed Original ResearchConceptsPartial thromboplastin timeLupus anticoagulantFVIII inhibitorsAsymptomatic patientsFactor VIIIComprehensive hematologic evaluationLife-threatening hemorrhageTypical laboratory findingsDistinctive clinical presentationFactor VIII inhibitorsRisk of thrombosisSigns of hemorrhageSevere bleeding diathesisCoagulation factor VIIIImmunosuppressive therapyClinical presentationClinical symptomsPathologic antibodiesVIII inhibitorsLaboratory findingsHematologic evaluationUnique presentationBleeding diathesisThromboplastin timeAutoantibodiesA Reliable Prognostic Marker for Liver Dysfunction in COVID-19 Infection
Anushiravani A, Khosravi B, Saberzadeh-Ardestani B, Ghasemi A, Kalantari S, Sorouri M, Mojtabavi H, Ghaemi O, Radmard A, Kasaeian A, Motamedi O, Poustchi H, Sima A. A Reliable Prognostic Marker for Liver Dysfunction in COVID-19 Infection. Middle East Journal Of Digestive Diseases 2021, 13: 193-198. PMID: 36606213, PMCID: PMC9489456, DOI: 10.34172/mejdd.2021.225.Peer-Reviewed Original ResearchIntensive care unitChest Computed TomographyLiver function testsFasting blood sugarC-reactive proteinPartial thromboplastin timeFatty liver changesFatty liver diseaseFunction testsCT scanProthrombin timeSpiral chest computed tomographyLiver diseaseLiver enzymesAbnormal liver function testsAlanine transaminaseAssociated with ICU admissionIntensive care unit admissionLiver changesAbnormal liver enzymesChest CT scanLow-density lipoprotein (LDL) levelsElevated alanine transaminaseNucleic acid testingLength of admission
2020
Coagulopathies Are a Risk Factor for Adverse Events Following Total Hip and Total Knee Arthroplasty.
Malpani R, Mclynn RP, Bovonratwet P, Bagi PS, Yurter A, Mercier MR, Rubin LE, Grauer JN. Coagulopathies Are a Risk Factor for Adverse Events Following Total Hip and Total Knee Arthroplasty. Orthopedics 2020, 43: 233-238. PMID: 32674174, DOI: 10.3928/01477447-20200624-02.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overArthroplasty, Replacement, HipArthroplasty, Replacement, KneeBlood Coagulation DisordersDatabases, FactualFemaleHumansMaleMiddle AgedMultivariate AnalysisOutcome Assessment, Health CarePatient ReadmissionPostoperative ComplicationsRetrospective StudiesRisk FactorsYoung AdultConceptsHigher international normalized ratioInternational normalized ratioMajor adverse eventsTotal hip arthroplastyPartial thromboplastin timeHigher partial thromboplastin timeMinor adverse eventsAdverse eventsLow plateletsHematological conditionsSurgeons National Surgical Quality Improvement Program databaseNational Surgical Quality Improvement Program databaseTotal knee arthroplasty (TKA) populationQuality Improvement Program databasePrimary total hip arthroplastyDependent functional statusImprovement Program databasePostsurgical adverse eventsTotal knee arthroplastyMultiple adverse eventsPreoperative coagulopathyTHA cohortTKA groupTKA patientsHospital readmissionEpidemiology of Hemostatic Transfusions in Children Supported by Extracorporeal Membrane Oxygenation.
Karam O, Goel R, Dalton H, Nellis ME. Epidemiology of Hemostatic Transfusions in Children Supported by Extracorporeal Membrane Oxygenation. Critical Care Medicine 2020, 48: e698-e705. PMID: 32697511, DOI: 10.1097/ccm.0000000000004417.Peer-Reviewed Original ResearchConceptsExtracorporeal membrane oxygenationCollaborative Pediatric Critical Care Research NetworkChest tube outputMembrane oxygenationHemostatic transfusionsRBC transfusionTransfusion doseExtracorporeal membrane oxygenation daysLarge observational cohort studyEunice Kennedy Shriver National InstituteCritical Care Research NetworkTube outputPlatelet transfusion doseObservational cohort studyHuman Development Collaborative Pediatric Critical Care Research NetworkInternational normalized ratioTotal platelet countPartial thromboplastin timeAntithrombin levelsCohort studyConsecutive childrenTransfusion strategyChest tubePlatelet countHemostatic testingThe Application of ROTEM in a Parturient With Antiphospholipid Syndrome in the Setting of Anticoagulation for Cesarean Delivery: A Case Report.
Fiol AG, Fardelmann KL, McGuire PJ, Merriam AA, Miller A, Alian A. The Application of ROTEM in a Parturient With Antiphospholipid Syndrome in the Setting of Anticoagulation for Cesarean Delivery: A Case Report. A&A Practice 2020, 14: e01182. PMID: 32224689, DOI: 10.1213/xaa.0000000000001182.Peer-Reviewed Case Reports and Technical NotesConceptsAntiphospholipid syndromeHeparin neutralizationDiagnosis of hemolysisElevated liver enzymesSetting of anticoagulationFresh frozen plasmaPartial thromboplastin timeCesarean deliveryLow plateletsTransfusion managementCase reportFrozen plasmaLiver enzymesThromboplastin timeParturientsSyndromeIntrinsic pathwayAnticoagulationROTEMDiagnosisNeutralizationHeparin
2018
Phase 1, single‐dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia
Gruppo R, Malan D, Kapocsi J, Nemes L, Hay C, Boggio L, Chowdary P, Tagariello G, von Drygalski A, Hua F, Scaramozza M, Arkin S, Investigators F, Hermans C, Claes C, Hanes I, Huyghe I, Kantaridis C, da Costa L, Ndongo M, Petit W, Santagostino E, Cannavo A, Fasulo M, Mancuso M, Tosetto A, Castaman G, Candiotto L, Radossi P, Scarpa E, Smith M, Dick A, Robson R, Waaka D, Wynne C, Punt Z, Kavakli K, Balkan C, Duyu M, Goksel S, Karapinar B, Ozyurek A, Saydam G, Karapinar D, Laffan M, Millar C, Suppiah P, Rizleigh C, Chowdary G, Davies J, Fosbury E, Gill S, Pike G, Thachil J, Recht M, Deutsche J, Taylor J, Kalinyak K, Mullins E, Palumbo J, Quinn C, Tarango C, Tarabar S, Chandler P, Deats L, Deshpande S, Epstein N, Hansson A, Pawlak S, Rudin D, Valentino L, Kakodkar N, Simpson M, Fogarty P, Bach T, Chiang E, Adamson J, Glass C, Sidhu N, Tucker‐Greene T. Phase 1, single‐dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. Journal Of Thrombosis And Haemostasis 2018, 16: 1984-1993. PMID: 30151972, DOI: 10.1111/jth.14247.Peer-Reviewed Original ResearchConceptsHemophilia AAdverse eventsSevere haemophiliaPhase 1 dose-escalation trialAssociated with dose-limiting toxicityTreatment of hemophilic patientsDose-limiting toxicityCongenital hemophilia ANon-bleeding patientsOpen-label studyActivated partial thromboplastin timeSevere hemophilia ADose-dependent shorteningIncreased procoagulant activityThrombin generation assayPartial thromboplastin timeTerminal half-lifeEvaluation of PKDuration of actionVital sign changesEscalation trialFIX inhibitorsSingle-doseSecondary endpointsLaboratory abnormalitiesOutcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia
Ramos GP, Binder M, Hampel P, Braga Neto MB, Sunjaya D, Al Bawardy B, Abu Dayyeh BK, Buttar NS, Bruining DH, Prabhu-Coelho N, Larson MV, Wong Kee Song LM, Rajan E. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointestinal Endoscopy 2018, 88: 55-61. PMID: 29408558, DOI: 10.1016/j.gie.2018.01.028.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCause of DeathCohort StudiesComorbidityEndoscopy, GastrointestinalErythrocyte TransfusionFemaleGastrointestinal HemorrhageHematemesisHemostasis, SurgicalHumansHypotensionIntensive Care UnitsInternational Normalized RatioLiver CirrhosisLung DiseasesMaleMelenaMiddle AgedMortalityPartial Thromboplastin TimePlatelet TransfusionRecurrenceRetrospective StudiesRisk FactorsSeverity of Illness IndexThrombocytopeniaYoung AdultConceptsIncreased international normalized ratioOvert gastrointestinal bleedingInitial hemostasis rateRecurrent bleeding rateGastrointestinal bleedingLiver cirrhosisSevere thrombocytopeniaPlatelet transfusionsPlatelet countTherapeutic yieldRecurrent bleedingHemostasis rateAdverse eventsBleeding rateHigh initial hemostasis rateIntensive care unit admissionCare unit admissionPredictors of mortalityCause mortality ratesMedian platelet countHours of presentationInternational normalized ratioSetting of thrombocytopeniaProcedural adverse eventsPartial thromboplastin time
2016
Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome
Wallace N, Dumont A, Burns A, Christopher T, Rinder H, Kriegel M, Buckley L, Erkan D, Lee A. Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome. Blood 2016, 128: 4983. DOI: 10.1182/blood.v128.22.4983.4983.Peer-Reviewed Original ResearchLupus anticoagulant-hypoprothrombinemia syndromePartial thromboplastin timeAntiphospholipid syndromeImmune thrombocytopeniaAntiphospholipid antibodiesAPS patientsProthrombin timeCessation of anticoagulationGlycoprotein 1 antibodiesObstetrical antiphospholipid syndromeRole of thromboelastographySevere hemorrhagic complicationsSpecific coagulation defectsCatastrophic antiphospholipid syndromeChronic liver diseaseGlobal hemostasis assaysTraditional laboratory markersBaseline prolongationChronic aspirinPersistent positivityAdrenal hemorrhageAnticardiolipin antibodiesHemorrhagic complicationsImmunomodulatory treatmentAnticardiolipin IgG
2013
International survey on plasma transfusion practices in critically ill children
Karam O, Tucci M, Lacroix J, Rimensberger PC, Network C. International survey on plasma transfusion practices in critically ill children. Transfusion 2013, 54: 1125-1132. PMID: 24032693, DOI: 10.1111/trf.12393.Peer-Reviewed Original ResearchConceptsTraumatic brain injuryPediatric critical care physiciansPlasma transfusion practicesInternational normalized ratioCritical care physiciansPlasma transfusionTransfusion practiceCare physiciansRed blood cell transfusion practicesAbnormal international normalized ratioPediatric critical care unitCardiac postoperative patientsTransfusion practice patternsSeptic shock patientsDemographic characteristicsCritical care unitsPartial thromboplastin timeProportion of physiciansFallot correctionNonbleeding patientsMinor bleedingShock patientsTransfusion thresholdPostoperative patientsSeptic shock
2010
WAG‐F8m1Ycb rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A
BOOTH CJ, BROOKS MB, ROCKWELL S, MURPHY JW, RINDER HM, ZELTERMAN D, PAIDAS MJ, COMPTON SR, MARKS PW. WAG‐F8m1Ycb rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A. Journal Of Thrombosis And Haemostasis 2010, 8: 2472-2477. PMID: 20626616, DOI: 10.1111/j.1538-7836.2010.03978.x.Peer-Reviewed Original ResearchConceptsAutosomal locationX chromosomeGenetic basisFactor VIIITertiary structureChromosome 18Point mutationsA1 domainFactor activityGenetic defectsHuman recombinant factor VIIIPartial thromboplastin timeSpecific coagulation factorsNew animal modelNormal prothrombin timeFactor VIII gene mutationsRecombinant factor VIIIMutationsPeripartum deathsGene mutationsCoagulation abnormalitiesSpontaneous bruisingProthrombin timeFemale ratsNovel therapies
2004
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB, Investigators A. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). The American Journal Of Cardiology 2004, 94: 279-283. PMID: 15276088, DOI: 10.1016/j.amjcard.2004.04.019.Peer-Reviewed Original ResearchMeSH KeywordsAgedConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansIncidenceIntracranial HemorrhagesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPartial Thromboplastin TimeProbabilityRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival RateTenecteplaseThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeConceptsWeight-adjusted heparinST-elevation myocardial infarctionASSENT-3Myocardial infarctionASSENT-2Major bleedingIntracranial hemorrhageSmall doseFull-dose tenecteplaseLess major bleedingNew thrombolytic regimenOutcomes of patientsAcute myocardial infarctionPartial thromboplastin timeSimilar ratesRefractory ischemiaThrombolytic regimenRecurrent infarctionBaseline characteristicsHemorrhagic complicationsUnfractionated heparinThromboplastin timePatientsInfarctionTenecteplase
2001
The Effects of Heparin, Protamine, and Heparin/Protamine Reversal on Platelet Function Under Conditions of Arterial Shear Stress
Griffin M, Rinder H, Smith B, Tracey J, Kriz N, Li C, Rinder C. The Effects of Heparin, Protamine, and Heparin/Protamine Reversal on Platelet Function Under Conditions of Arterial Shear Stress. Anesthesia & Analgesia 2001, 93: 20-27. PMID: 11429331, DOI: 10.1097/00000539-200107000-00005.Peer-Reviewed Original ResearchConceptsCollagen-induced thrombus formationPlatelet hemostasis timePartial thromboplastin timeAntiplatelet effectProthrombin timeAntithrombin effectPlatelet activationProtamine reversalPlatelet functionDirect antiplatelet effectCollagen-dependent platelet activationDirect thrombin inhibitorL-arginyl-chloromethyl ketoneClot Signature AnalyzerEffect of heparinCollagen-induced platelet activationEffect of protamineArterial shear stressBlood lossCardiopulmonary bypassPlatelet dysfunctionProtamine ratioPlatelet aggregometryAnticoagulant effectThromboplastin time
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply